HONG KONG – China has approved the fourth homegrown CD47 antibody to start clinical trials, intensifying the local CD47 race. Chinese biologics developer I-Mab Biopharma (Shanghai) Co. Ltd. said it received the go-ahead for the clinical study of TJC-4, its differentiated fully human CD47 monoclonal antibody for treating advanced malignant tumors. Read More
HONG KONG – Sinomab Bioscience Ltd., a Hong Kong clinical-stage antibody firm, said its application for a Hong Kong IPO was accepted by the stock exchange, making it the 16th biopharma to submit an application under the new rules of the Hong Kong Exchange (HKEX). Read More
MEXICO CITY – The 2019 International AIDS Society (IAS) Conference on HIV Science kicked off over the weekend with the usual pre-conference workshops, including a workshop by the IAS Towards an HIV Cure initiative. Read More
HONG KONG –Biocure Technology Corp., a Canadian biopharmaceutical company focusing on biosimilar products, is advancing a CAR T product through its South Korean subsidiary, Biocurepharm Inc., thanks to a recently closed private placement. Read More
Immuron Ltd., of Melbourne, Australia, priced a public offering of 339,130 American depositary shares (ADSs), each representing 40 ordinary shares, offered at a price of $4 per ADS, for gross proceeds of about $1.4 million. The company also granted a 45-day option for the underwriter to acquire an additional 50,869 ADSs to cover overallotments. Read More
HONG KONG – Singaporean biotech company Aum Biosciences Pte. Ltd. has in-licensed a potentially first-in-class PIM/PI3K/mTOR inhibitor from Inflection Biosciences Ltd., of Dublin and London, to develop it globally to treat a wide range of cancers. Read More
